drugset / Trial / NCT00274612

Prospective Randomised Investigation of the Safety and Efficacy of Micardis® vs Ramipril Using ABPM

NCT00274612

Phase 4 Completed 801 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study is to demonstrate that telmisartan 80 mg (MICARDIS®) is at least as effective and possibly superior to ramipril 5mg and 10mg in lowering mean ambulatory diastolic blood pressure (DBP) and systolic blood pressure (SBP) during the last 6 hours of the 24-hour dosing interval in mild-to-moderate hypertensive patients at the end of an 8 and 14-week treatment period, respectively.

Timeline

Start
2002-10
Primary completion
2003-11
Completion
2003-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Ramipril Small molecule 5 mg
Subject Ramipril Small molecule 10 mg
Subject Telmisartan Other / unclassified 80 mg

Indications